Case report of simultaneous presentation of pulmonary embolism and pericardial effusion following an oncological esophagectomy

Jou-Valencia, Daniela; Dijkstra, Frederieke A.

Published in:
International journal of surgery case reports

DOI:
10.1016/j.ijscr.2020.10.090

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Jou-Valencia, D., & Dijkstra, F. A. (2020). Case report of simultaneous presentation of pulmonary embolism and pericardial effusion following an oncological esophagectomy. International journal of surgery case reports, 77, 252-255. https://doi.org/10.1016/j.ijscr.2020.10.090

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment.

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Case report of simultaneous presentation of pulmonary embolism and pericardial effusion following an oncological esophagectomy

Daniela Jou-Valencia 1, Frederieke A. Dijkstra *
Department of Surgery, University of Groningen, University Medical Center Groningen (UMCG), Groningen, the Netherlands

A R T I C L E   I N F O
Article history:
Received 25 August 2020
Accepted 20 October 2020
Available online 28 October 2020

Keywords:
Esophageal cancer
Esophageal resection
Case report
Pulmonary embolism
Pericardial effusion
Direct oral anticoagulant (DOAC)

A B S T R A C T

INTRODUCTION: This is the first reported case of simultaneous presentation of pulmonary embolism and pericardial effusion following esophagectomy. This case illustrates a diagnostic and therapeutic challenge exemplifying the difficulties arising from complex anticoagulant considerations in esophageal cancer.

PATIENT CASE: A 72 year old male undergoes an oncological esophageal resection. Postoperatively the patient develops pulmonary embolism for which he is treated with Rivaroxaban. After starting Rivaroxaban the patient develops a large pericardial effusion.

DISCUSSION: We suspect that the treatment of pulmonary embolism with Rivaroxaban had a causative role in the development of pericardial effusion. Based on literature we suspect that chemoradiotherapy increased susceptibility.

CONCLUSION: Diagnosis and treatment of simultaneous pulmonary embolism and pericardial effusion remains a challenge. Special consideration should be taken when using Rivaroxaban in esophageal cancer patients; this should always be conducted in consultation with a coagulation specialist.

© 2020 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Esophageal cancer (EC) is a serious diagnosis with high morbidity and mortality. Treatment involves chemoradiotherapy and esophageal resection. This is a complex procedure with a high risk of complications [1].

We present a case of a 72-year-old male with progressive chest pain (CP) and shortness of breath (SoB) following an uncomplicated esophagectomy in a University Medical Center in the Netherlands. The symptoms were initially attributed to a massive pulmonary embolism (PE) for which Rivaroxaban was started. Six days after, a pericardial effusion (Pce) was seen on CT alongside the PE.

This is the first reported case of the simultaneous presentation of PE and Pce following esophagectomy. This case illustrates a diagnostic and therapeutic challenges, exemplifying the difficulties arising from complex anticoagulant considerations in EC.

The case is presented according to SCARE criteria [2].

2. Presentation of case

A 72 year-old Caucasian male (Table 1) was diagnosed with distal esophageal squamous cell carcinoma (ct2N1M0) for which he received carboplatin/paclitaxel chemoradiotherapy. After 5 cycles, positron emission tomography showed complete response to therapy. Due to the aggressive nature of the cancer, an esophageal resection was indicated. Twelve weeks after the last chemoradiotherapy session the patient underwent a robot-assisted minimally-invasive esophagectomy with intra-thoracic anastomosis. Procedure was executed by two experienced upper GI surgeons.

On postoperative day (POD) 2 the patient developed SoB and CP. This was initially deemed reflective of recent post-operative status, however a progression in symptoms warranted additional imaging. A CT on POD 6 showed bilateral PE (left being segmental) with infarction of the right lower lobe and bilateral consolidations suggestive of pneumonia (Fig. 2). Therapeutic fraxiparine 2dd1 7600IE and antibiotics were immediately administered.

On POD7 the patient became acutely dyspneic requiring admission to the intensive care with acute respiratory failure secondary to PE and pneumonia. ECG showed atrial fibrillation. In the blood, a doubling of CRP (350 mg/L) with leukocytes of 15.50 × 10⁹/L and stable hemoglobin were observed (Fig. 1). Optiflow and amiadaron were started, after which respiratory status improved and the arrhythmia converted to sinus rhythm. The patient was transferred back to the surgical ward where he continued to recuperate.

On POD13 the patient was switched to Rivaroxaban 2dd15 mg (Fig. 1), as this was deemed a better treatment for the arrhythmia and PE. Due to anxiety quetiapine 1dd12.5 mg, and lorazepam 1dd10 mg were also initiated.

Despite treatment, symptoms of SoB and CP continued to progress. Elevated CRP of 100 mg/L and leukocytes of 13.0 × 10⁹/L suggested the symptoms were due to the PE and pneumonia. On
POD17 a hypotensive episode (94/68 mmHg) with a regular heart rate of 96bpm was observed. X-thorax showed bilateral pleural fluid and an enlarged heart. On CT a massive PcE was seen with pleural fluid, bilateral consolidations, and mediastinal air pockets suggestive of an anastomotic leakage (AL) (Fig. 2). A transthoracic echocardiogram showed substantial pericardial fluid with no signs of imminent tamponade. Rivaroxaban was stopped, and via pericardio-centesis 1150 mL of fluid was aspirated from the pericardium.

Fig. 1. Vital signs, laboratory findings and anticoagulation scheme during postoperative admission; CRP: C-Reactive Protein. Addendum 1: Clinical course.
Table 1
Patient Characteristics.

| Baseline characteristics | Medical History | Medication | Allergies | Intoxications | Social Context |
|---------------------------|-----------------|------------|-----------|---------------|---------------|
| Age 72 years              | 2001 Myocardial infarction | Lorazepam 1 mg once a day, at night | None | Smoking Yes, quit in 2001 | Marital status Married |
| Gender Male               | 2003/12 Peripheral T-Cell Non-Hodgkin Lymphoma | Rosuvastatin 5 mg once a day | Alcohol Yes, 6 glasses of alcohol per week | Alcohol Never | Employment Manager wholesale glass company: retired |
| Race Caucasian            | 2004/09 Recurrence T-cell Non-Hodgkin Lymphoma | Carbamazepine 100 mg powder once a day | Drug Neuraxial | Drug Neuraxial |                    |
| BMI 2596 kg/m²            | 2016 Colon carcinoma, pT3N0Mo | Perindopril 2 mg once a day | Allergy | Allergy |                    |
|                           | 2019/03 Esophageal cancer, ct2N1Mo | | | |                    |
|                           |                             | Left hemicolectomy | | |                    |
|                           |                             | Neoadjuvant chemotherapy | | |                    |
|                           |                             | (carboplatin/paclitaxel) | | |                    |

BMI: Body Mass Index; PTCA: percutaneous transluminal coronary angioplasty; CHOP: combination chemotherapy used for treatment of non-Hodgkin Lymphoma; DHAP/VIM/DHAP: combination chemotherapy used for treatment of non-Hodgkin Lymphoma.

Figure 1
Computed Tomography postoperative Day 6 + Day 21.

3. Discussion and conclusion

This is the first reported case of the simultaneous presentation of PE and PCe following esophagectomy. The case poses diagnostic and therapeutic challenges arising from complex anticoagulation considerations.

There are few reported cases of PCe following an esophagectomy [3,4]. This procedure requires the surgeon to work in close proximity to the pericardium in order to dissect and prepare the esophageal tissue for resection. Surgical trauma may precipitate the development of a PCe shortly following surgery. In our case, the PCe was diagnosed on POD20, suggesting that surgical trauma played no direct role in its development.

A systematic review by Pabba et al. [5] presents 7 cases of concurrent PE and PCe in cancer patients, with PCe deemed secondary to malignancy based on cytological fluid analyses. In our case, cytological and pathology results showed no malignant cells. Another common cause of PCe is infection. We found no evidence of elevated white blood cells or microorganisms in cytology, suggesting an alternative cause of PCe.

Our patient received preoperative chemoradiotherapy. Several observational studies on the incidence of PCe following chemoradiotherapy for EC report an incidence of 27.7–57.0% with a median onset of 5.3–12 months following the last chemoradiotherapy session [6,7]. In our case, the PCe was diagnosed approximately 15 weeks after the last chemoradiotherapy session, suggesting that the chemoradiotherapy may have played a role in the development of PCe.

Considering the timeline, SoB and CP symptoms worsened one day after the start of Rivaroxaban. At this time, we see a downward trend in hemoglobin levels—possibly indicating an active bleed. The fact that the patient did not develop a cardiac tamponade despite having almost 1200 mL of blood in the pericardium, suggests that the blood accumulated slowly. Together, this draws suspicion towards Rivaroxaban as the PCe cause. A case series by Cinelli et al. (2019) [8] presents three cases of direct oral anticoagulants (DOAC)-induced PCe in oncologic patients. All three cases showed malignant cells in fluid cytology, suggesting that this may have played a causative role rather than Rivaroxaban.

The current standard of treatment for PE is therapeutic low molecular weight heparin (LMWH). Studies within the general population presented DOACs as an appropriate, patient friendly alternative to LMWH for the treatment of Venous Thromboembolism (VTE). Although encouraging, these studies underrepresented oncologic patients [9]. Two recent randomized controlled trials looked at the effectiveness of DOACs compared to LMWH for the treatment of VTE in cancer patients [10,11]. They showed a decreased incidence of recurrent VTE, with an increased risk of bleeding amongst the DOAC group. This risk was primarily observed in upper gastrointestinal malignancies, with emphasis on esophageal and gastric cancer. Within the esophageal group, bleeding was only noted in unresected esophageal tumors. This

Pathological assessment of the fluid showed blood without malignant cells. A cytogram showed erythrocytes, a few leukocytes, no bacteria nor other microorganisms. Therapeutic fraxiparine was resumed 8 h post-pericardiocentesis. Intravenous antibiotics were administered in treatment of the lung consolidations. A small defect at the anastomosis was gastroscopically confirmed, and treated conservatively with antibiotics and nil by mouth.

Following pericardiocentesis the CP and SoB symptoms improved. X-thorax showed reduced heart contours and pleural fluid. ECG showed sinus rhythm. Laboratory workup showed normalization of infection parameters. The patient was observed for another 5 days without complications before he was discharged from hospital.
suggests that the bleeding in this patient group mainly involved tumour tissue. However, due to the limited number of EC patients in these studies, further research is necessary before firm conclusions can be formulated. Special attention should be given to the uptake of DOACs in EC patients. Studies looking at the effects of bariatric surgery and gastrointestinal resections on DOAC uptake have shown an inadequate absorption of the drug resulting in suboptimal anticoagulation [12]. This is suggestive of a similar problem amongst esophagectomy patients.

Lastly, Rivaroxaban is a substrate of the P-gp efflux transporter, and is metabolized via CYP3A. Medications interactions with these systems can cause changes in medication concentrations [13]. Qutapine, the antipsychotic which our patient received, acts as a P-gp and CYP3A inhibitor. Both interactions can result in an increased plasma concentration of Rivaroxaban and increasing the risk of bleeding, and potentially playing a role in the development of PE in our patient.

In conclusion, this case illustrates the diagnostic challenges of SoB and CP in post-esophagectomy patients, as well as the difficulties arising from complex anticoagulant considerations in EC. There is conflicting evidence regarding the safety of Rivaroxaban in EC patients, with no evidence of its uptake following an esophageal resection. In our patient case we suspect that the treatment of PE with Rivaroxaban had a causative role in the development of PEc and based on literature we also suspect that chemoradiotherapy increased susceptibility. Based on current literature and this case study we believe that the use of Rivaroxaban in EC patients should always be conducted in consultation with a coagulation specialist.

Declaration of Competing Interest
The authors report no declarations of interest.

Funding
None.

Ethical approval
Not applicable. Informed consent from patient obtained.

Consent
Informed consent from patient obtained.

Registration of research studies
Case study: Not applicable.

Guarantor
The first and last author (Daniela Jou-Valencia MD4; Frederieke A. Dijkstra MD) accept full responsibility for the study and guarantee its accuracy.

Provenance and peer review
Not commissioned, externally peer-reviewed.

CRediT authorship contribution statement
Daniela Jou-Valencia: Conceptualization, Data curation, Writing - original draft. Frederieke A. Dijkstra: Supervision, Writing - review & editing.

References
[1] D. Low, M. Kuppusamy, … D.A.-A. of, undefined 2019, Benchmarking complications associated with esophagectomy, Cdn.Journals.Jlw.Com, (nd). https://cdn.journals.lww.com/amastuffsurgery/fulltext/2019/02000/ Benchmarking_Comlications_Associated_with_17.aspx?exportImagesToPtpl=true&exportImagesToTpf=true&exportImages ToPtrue=true&exportImagesToTpf=true&exportImagesToPtrue=true. (Accessed 18 October 2019).
[2] R.A. Agha, M.R. Borrelli, R. Farwana, K. Koshy, A.J. Fowler, D.P. Orgill, H. Zhu, A. Alsawadi, A. Noureldin, A. Rao, A. Enam, A. Thoma, M. Bashashati, B. Vasudevan, A. Beamish, B. Challacombe, R.I. De Wilde, D. Machado-Andara, D. Laskin, D. Muzumdar, A. D’Crus, T. Manning, D. Healy, D. Papano, P. Goel, P. Ranganathan, P.S. Pai, S. Raja, M.H. Ather, H. Kaduozu, I. Nixon, I. Mukhterjee, J. Gómez Rivas, K. Raveendran, L. Derbyshire, M. Valmasoni, M. Chalko, N. Raison, O. Muensterer, P. Bradley, C. Roberto, R. Affi, D. Rosin, K. Klappenbach, R. Wynn, S. Giordano, S. Basu, S. Surani, P. Suman, M. Theorat, V. Kasi, The SCARE 2018 statement: updating consensus Surgical Case Report (SCARE) guidelines, Int. J. Surg. 60 (2018) 132–136, http://dx.doi.org/10.1016/j.isu. 2018.10.026.
[3] A.M. Coker, J.S. Barajas-Gamboa, J. Cheverie, G.R. Jacobsen, B.J. Sandler, M.A. Talamini, M. Bouvet, S. Horgan, Outcomes of robotic-assisted transhiatal esophagectomy for esophageal cancer after neoadjuvant chemoradiation, J. Laparoendosc. Adv. Surg. Tech. 24 (2014) 89–94, http://dx.doi.org/10.1097/SLA. 2013.044.
[4] S. Kats, G.A.P. Nieuwenhuijzen, B.H.M. van Straten, J.P.A.M. Schoonberger, Cardiac tamponade: an unusual, lifethreatening complication after transhiatal resection of the esophagus, Intact. Cardiovasc. Thorac. Surg. 6 (2006) 238–239, http://dx.doi.org/10.1151/icvts.2006.145631.
[5] K. Pabba, C.M. Rojas-Hernandez, Concurrent presentation of a hemorrhagic pericardial effusion and venous thromboembolism in malignancy: a systematic review of case studies, J. Thromb. Thrombolysis 48 (2019) 454–458, http://dx.doi.org/10.1007/s11239-019-01884-z.
[6] X. Wei, H.H. Liu, S.L. Tucker, S. Wang, R. Mohan, J.D. Cox, R. Komaki, Z. Liao, Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy, Int. J. Radiat. Oncol. Biol. Phys. 70 (2008) 707–714, http://dx.doi.org/10.1016/j.ijrobp.2007.10.056.
[7] K. Tamari, F. Ishinishi, Y. Akino, Y. Suzuki, Y. Seo, Y. Yoshikawa, Y. Hayashi, T. Nishida, T. Takehara, M. Mori, Y. Doki, K. Ogawa, Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy, Anticancer Res. 34 (2014) 7389–7393, http://dx.doi.org/10.1136/ncbi. nih.gov/pubmed/25503178, (Accessed 8 October 2019).
[8] M. Cinelli, A. Uddin, I. Duka, A. Soomro, F. Tamburino, F. Ghavami, J. Laferty, Spontaneous hemorrhagic pericardial and pleural effusion in a patient receiving apixaban, Cardiol. Res. 10 (2019) 249–252, http://dx.doi.org/10. 14740/cr0502.
[9] C. Ay, J. Beyer-Westendorf, I. Pabinger, Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants, Ann. Oncol. 30 (2019) 897–907, http://dx.doi.org/10.1093/annonc/mdz111.
[10] A.M. Young, A. Marshall, J. Thirwall, O. Chapman, A. Lokare, C. Hill, D. Hale, J.A. Dunn, G.H. Lyman, C. Hutchinson, P. MacCallum, A. Kalkkari, F.D.R. Hobbs, S. Petrou, J. Dale, C.J. Poole, A. Maraveyas, M. Levine, Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D), J. Clin. Oncol. 36 (2018) 2017–2023, http://dx.doi.org/10.1200/JCO.2018.78.8034.
[11] G.E. Raskob, N. van Es, P. Verhamme, M. Carrier, M. Di Nisio, D. Garcia, M.A. Grosso, A.K. Kakkar, M.J. Kovacs, M.F. Mercuri, G. Meyer, A. Segers, M. Shi, T.-F. Wang, E. Yeo, G. Zhang, J. Zwicker, J.L. Weitz, H.R. Buller, Edoxaban for the treatment of cancer-associated venous thromboembolism, N. Engl. J. Med. 378 (2018) 615–624, http://dx.doi.org/10.1056/NEJMoa1711948.
[12] H.A. Hakeam, N. Al-Sanea, Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs), J. Thromb. Thrombolysis 43 (2017) 343–351, http://dx.doi.org/10.1007/s11239- 016-1405-x.
[13] T.A. Mavarakas, C. Samer, P. Fontana, A. Perrier, Direct oral anticoagulants: efficacy and safety in patient subgroups, Swiss Med. 145 (2015), http://dx.doi. org/10.4414/sm.2015.14081.